Channels

 

Special Offers & Promotions

 

 

Latest News

 

 

View Channel

New Products

 

 

View Channel

Video Presentations

 

 

View Channel

Separation Science

 

 

View Channel

Microscopy & Image Analysis

 

 

View Channel

Laboratory Automation & IT Solutions

 

 

View Channel

 

Axol Bioscience and Metrion Biosciences Announce Research Collaboration

publication date: Aug 29, 2016
 | 
author/source: Axol Bioscience

The human cell culture specialists join experts in ion channel research to study human iPSC-derived cardiomyocytes for drug discovery applications

axolAxol Bioscience, a biotechnology company specialising in the supply of human induced pluripotent stem cell (iPSC)-derived cells, and Metrion Biosciences, a specialist ion channel drug discovery business, have signed a collaboration agreement to improve, standardise and more accurately predict the risk of human clinical pro-arrhythmias. This is in accordance with the FDA’s Comprehensive in vitro Proarrhythmia Assay (CiPA) initiative, which aims to revise cardiac safety testing regulations.

Under the terms of the agreement, Metrion will use Axol’s human iPSC-derived cardiomyocytes to carry out ion channel screening, cardiac safety testing and translational phenotypic assays. Combining Metrion's contract research services and assay development capabilities with Axol’s human iPSC-derived cells and culture reagents will provide a source of well-validated, CiPA-compliant stem cell-derived assays and services for use in predictive toxicology as well as drug discovery screening.

Metrion already provides a range of services that meet some of the cardiac safety testing guidelines outlined in the CiPA paradigm, including a premium panel of human cardiac ion channel assays, providing high quality data for use in computer-based models of the human cardiac action potential to predict the risk of pro-arrhythmia. These results need to be confirmed in translational phenotypic assays, which will be carried out using Axol’s human iPSC-derived cardiomyocytes, to help ensure the results are physiologically relevant, and offer a more accurate prediction of drug liability to identify cardiac safety issues sooner and more cost-effectively.

Marc Rogers, PhD, Chief Scientific Officer of Metrion Biosciences, said: ‘The preliminary validation work we carried out using Axol Human iPSC-Derived Ventricular Cardiomyocytes show a physiological composition of the three main cardiac ion channels and appropriate cardiac pharmacology, making these cells a promising research tool for investigating CiPA liability.’

Yichen Shi, PhD, Chief Executive Officer of Axol Bioscience, said: ‘We value the insight and expertise Metrion’s team bring to this partnership. Working together we can be sure that our customers continue to get the most out of our products and services.’


more about axol bioscience


 



 

Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!

Newsletters from Lab Bulletin

 

Request your free copies HERE

 

 

 

Popular this Month

Top 10 most popular articles this month

 

 

Today's Picks

 


 

Looking for a Supplier?

Search by company or by product

 


Company Name:

Product:


 

 

 

 

Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd.


 

Media Partners

 

Exhibitions & Events